Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing?

Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population

(2010) Masakazu Toi et al.   CANCER

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers

(2010) Catherine M. Kelly et al.   CANCER

The Oncotype DX Recurrence Score Is Correlated With a Composite Index Including Routinely Reported Pathobiologic Features

(2010) Joseph Geradts et al.   CANCER INVESTIGATION

A Lower Allred Score for Progesterone Receptor Is Strongly Associated With a Higher Recurrence Score of 21-Gene Assay in Breast Cancer

(2010) Ping Tang et al.   CANCER INVESTIGATION

Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score – Results from TransATAC.:

(2010) J. Cuzick et al.   CANCER RESEARCH

Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients

(2009) Shuzhen Liu et al.   BREAST CANCER RESEARCH AND TREATMENT

Complementary Value of the Ki-67 Proliferation Index to the Oncotype DX Recurrence Score

(2009) Katja Gwin et al.   INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY

Autopsy

(2009)   MODERN PATHOLOGY

Prognostic Utility of the 21-Gene Assay in Hormone Receptor–Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features

(2008) Lori J. Goldstein et al.   JOURNAL OF CLINICAL ONCOLOGY

High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system

(2008) Allen M Gown et al.   MODERN PATHOLOGY

Histopathologic variables predict Oncotype DX™ Recurrence Score

(2008) Melina B Flanagan et al.   MODERN PATHOLOGY

Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients

(2007) Ido Wolf et al.   CANCER